| Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis |
ChiCTR1800017857: KN035 prospective single arm phase II clinical study on efficacy and safety in the treatment of patients with advanced multiple primary tumors |
|
|
| Not yet recruiting | 2 | 20 | | KN035 | Renji Hospital Affiliated to Medical School of Shanghai Jiaotong University; Renji Hospital, Shanghai shenkang hospital development center clinical science and technology innovation project - municipal hospital clinical research and cultivation project | Multiple primary tumors | | | | |
CISLD-12, NCT05213221: Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients |
|
|
| Completed | 2 | 39 | RoW | Envafolimab, TACE, Lenvatinib | Zhejiang University | Advanced Hepatocellular Carcinoma | 09/22 | 06/23 | | |
NCT05298020: Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer |
|
|
| Not yet recruiting | 2 | 20 | RoW | Envafolimab, Immunotherapy, Endostar, endostatin, Nab paclitaxel, Chemotherapy, Gemcitabine | The Affiliated Hospital of Xuzhou Medical University | Advanced Pancreatic Cancer | 12/22 | 04/23 | | |
| Not yet recruiting | 2 | 20 | RoW | Envafolimab, Immunotherapy, Lenvatinib, Tyrosine kinase inhibitors, VP-16, Chemotherapy | Zhongda Hospital | Ovarian Cancer, Epithelial | 12/22 | 12/23 | | |
NCT05237349: Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma |
|
|
| Recruiting | 2 | 38 | RoW | Envafolimab, Immunotherapy, Oxaliplatin, Chemotherapy, S1 | Liangjun Zhu M.M., Zhangjiagang First People's Hospital | Metastatic or Recurrent Gastric Adenocarcinoma | 12/24 | 12/24 | | |
PRECAM, NCT05216653: Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 32 | RoW | Envafolimab, KN053, Oxaliplatin, Capecitabine, Short-course Radiation, TME surgery, total mesorectal excision | Sir Run Run Shaw Hospital | MSS Locally Advanced Rectal Adenocarcinoma | 03/23 | 03/25 | | |
SLKYLX2023-006, NCT06239870: Single-arm, Single-center, Exploratory Phase II Clinical Study of Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer |
|
|
| Recruiting | 2 | 35 | RoW | Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy | Yunnan Cancer Hospital, Beijing Bethune Charitable Foundation | Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer | 09/25 | 09/25 | | |
NCT05335460: To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer |
|
|
| Not yet recruiting | 2 | 36 | NA | Envafolimab, XELOX( Oxaliplatin 130mg/m2,ivgtt, Q3w capecitabine 1000mg/m2, p.o Q3w) | Fujian Cancer Hospital | Colon Cancer | 05/23 | 05/24 | | |
NSCLC-LXL002, NCT05360979: A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC |
|
|
| Enrolling by invitation | 2 | 42 | RoW | envafolimab, recombinant human endostatin, chemotherapy | Second Xiangya Hospital of Central South University | Non-small Cell Lung Cancer | 05/23 | 05/25 | | |
NCT05551247: Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 30 | NA | Envafolimab, recombinant human endostatin (endostatin) | First Affiliated Hospital Xi'an Jiaotong University | Colorectal Neoplasms | 06/23 | 06/24 | | |
ChiCTR1900021607: A Phase II, Single-arm and Open-labelled Clinical Study of Anti-PD-L1 Antibody KN035 Combined with Trastuzumab and Docetaxel in the Treatment of HER2-positive Advanced Breast Cancer |
|
|
| Recruiting | 2 | 59 | | Conventional chemotherapy (TH regimen) combined with KN035 5mg/kg/3w | Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Natural Science Foundation of China (81622036) | breast cancer | | | | |
| Active, not recruiting | 2 | 207 | RoW | ASC22, sodium chloride | Ascletis Pharmaceuticals Co., Ltd., Peking University First Hospital, Beijing Clinical Service Center | Chronic Hepatitis b | 08/24 | 08/24 | | |
NCT05148195: A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors |
|
|
| Terminated | 2 | 86 | RoW | Envofolimab, BD0801, Docetaxel, Irinotecan, Leucovorin calcium, 5-Fluorouridine | Jiangsu Simcere Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 07/23 | 07/23 | | |
NCT05387681: Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric |
|
|
| Not yet recruiting | 2 | 35 | NA | Envafolimab, Endostatin | Wuhan Union Hospital, China | Gastric/Gastroesophageal Junction Adenocarcinoma, Radiotherapy, Immunotherapy | 07/23 | 12/25 | | |
NCT05529355: Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | 2 | 45 | NA | Envafolimab plus Endostar and S-1, Envafolimab combined with Recombinant Human Endostatin Injection/Tegafur,Gimeracil and Oteracil Porassium Capsules, Envafolimab plus Endostar, Envafolimab combined with Recombinant Human Endostatin Injection, Envafolimab plus S-1, Envafolimab combined with Tegafur,Gimeracil and Oteracil Porassium Capsules | Anhui Chest Hospital | Carcinoma, Non-Small-Cell Lung | 09/23 | 09/23 | | |
NCT05582109: Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 30 | NA | Envafolimab, Lenvatinib Combined With TACE | Tianjin Medical University Cancer Institute and Hospital | Objective Response Rate (ORR) | 10/23 | 10/25 | | |
NCT05068427: Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. |
|
|
| Active, not recruiting | 2 | 34 | RoW | Chidamide, CS055, Envafolimab, KN035 | Chipscreen Biosciences, Ltd. | Non Small Cell Lung Cancer | 12/23 | 12/23 | | |
NCT05243355: Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC |
|
|
| Recruiting | 2 | 46 | RoW | "Envafolimab" and "Chemotherapy" and "Recombinant Human Endostatin" | Qilu Hospital of Shandong University | Squamous Non-small Cell Lung Cancer | 12/23 | 12/24 | | |
NCT05330143: Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV |
|
|
| Recruiting | 2 | 30 | RoW | ASC22 1mg/kg, KN035, ASC22 2.5mg/kg, Antiretroviral Therapy, Placebo | Ascletis Pharmaceuticals Co., Ltd. | HIV-1-infection, HIV Infections, PD-L1 Gene Mutation | 12/23 | 12/23 | | |
NCT06143579: A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 48 | NA | FOLFOX-HAIC+Lenvatinib+Envolizumab, KN035 | Sun Yat-sen University | Potentially Resectable Hepatocellular Carcinoma | 03/25 | 12/26 | | |
NCT05552651: Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 40 | NA | Envafolimab, Albumin-Bound Paclitaxel, Carboplatin | Tao Jiang | Esophageal Squamous Cell Carcinoma | 12/23 | 12/23 | | |
| Recruiting | 2 | 200 | RoW | KN035 | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumor | 06/24 | 12/25 | | |
NCT05112991: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer |
|
|
| Recruiting | 2 | 108 | RoW | Envafolimab+Lenvatinib, Envafolimab | 3D Medicines (Sichuan) Co., Ltd. | Advanced Endometrial Cancer | 08/24 | 10/24 | | |
ChiCTR2400079718: Single-arm, single-center, exploratory Phase II clinical study of Envafolimab combined with chemoradiotherapy in the treatment of locally advanced pMMR/MSS rectal cancer |
|
|
| Recruiting | 2 | 35 | China | Enweida (envafolimab) - 3DMed, Tracon Pharma, Ascletis, capecitabine - Generic mfg. | Yunnan Cancer Hospital, Beijing Bethune Charitable Foundation | pMMR/MSS locally advanced rectal cancer | | | | |
NCT06218004: Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 40 | NA | Envafolimab combined with chemotherapy, Envafolimab | Hairong Liu | Efficacy and Safety | 12/25 | 12/25 | | |
NCT06202014: Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC |
|
|
| Recruiting | 2 | 43 | RoW | concurrent radiotherapy with envafolimab and capecitabine | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Pancreatic Cancer, Radiotherapy, Envafolimab, Capecitabine | 12/24 | 12/25 | | |
NCT06279754: Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy |
|
|
| Not yet recruiting | 2 | 30 | NA | Recombinant Human Endostatin Injection, Evafolimab Injection | The First Affiliated Hospital of Xinxiang Medical College | Locally Advanced Squamous Non-small Cell Lung Cancer | 06/24 | 12/25 | | |
ST-CR01, NCT05755009: High- and Low-dose Radiotherapy Combined With Envafolimab for Metastatic Solid Tumor |
|
|
| Recruiting | 2 | 33 | RoW | High- and Low-dose radiotherapy | Jiangxi Provincial Cancer Hospital | Metastatic Cancer | 02/24 | 02/25 | | |
NCT06301828: Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors |
|
|
| Recruiting | 2 | 16 | RoW | Envafolimab Injection, KN035, Endostar, Recombinant Human Endostatin Injection | Nanjing First Hospital, Nanjing Medical University | Gastrointestinal Neoplasms | 06/25 | 02/26 | | |
NCT06321081: ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC |
|
|
| Recruiting | 2 | 60 | RoW | irinotecan, cetuximab, envafolimab, CPT-11, PD-L1 inhibitor | Beijing Hospital, Bethune Charitable Foundation | RAS Mutation, Metastatic Colorectal Cancer, MSS | 02/26 | 08/26 | | |
NCT04891198: ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 2 | 126 | RoW | Envafolimab | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumor | 08/27 | 04/28 | | |
NCT05385185: Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer |
|
|
| Recruiting | 2 | 20 | RoW | Camrelizumab or envafolimab, Recombinant human vascular endostatin | Hebei Medical University | Leptomeningeal Metastasis, Immune Checkpoint Inhibitor, Endostatin | 05/24 | 12/24 | | |
| Recruiting | 2 | 40 | RoW | Envafolimab, EN WEI DA, Endostar, ENDO | The First People's Hospital of Lianyungang | Lung Neoplasms | 05/24 | 06/24 | | |
ENVASARC, NCT04480502: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma |
|
|
| Active, not recruiting | 2 | 207 | Europe, US | Envafolimab, KN035, Ipilimumab, Yervoy | Tracon Pharmaceuticals Inc. | Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | 10/24 | 10/24 | | |
NCT05414630: A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 2 | 30 | RoW | Envafolimab | Anhui Provincial Cancer Hospital | Non-small Cell Lung Cancer Stage III | 06/24 | 06/25 | | |
NCT05371197: Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer |
|
|
| Recruiting | 2 | 26 | RoW | Neoadjuvant therapy with PD-L1 inhibitor | Third Affiliated Hospital, Sun Yat-Sen University | Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy | 06/24 | 12/24 | | |
NCT06014372: Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 55 | RoW | Envafolimab, CAPEOX | Sun Yat-sen University | Colon Cancer, Neoadjuvant Therapy, Immunotherapy | 07/24 | 07/26 | | |
ChiCTR2100044981: a prospective, single-arm phase II clinical study of Envafolimab combined with carboplatin/cisplatin and etoposide in the first-line treatment of extensive-stage SCLC |
|
|
| Recruiting | 2 | 32 | | First-line treatment with Envolimab (Envafolimab) combined with carboplatin/cisplatin and etoposide, and 4 cycles later with Envafolimab (Envafolimab) monotherapy for maintenance until the disease progresses or becomes intolerable | Oncology Department of PLA General Hospital; The General Hospital of People's Liberation Army(301 hospital, Jiangsu Simcere Pharmaceutical Co., Ltd | Lung Cancer | | | | |
NCT05417230: RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2 |
|
|
| Not yet recruiting | 2 | 29 | NA | RC48-ADC, Envafolimab | Jiangsu Cancer Institute & Hospital | Biliary Tract Cancer | 08/24 | 08/25 | | |
ENLIGHTEN, NCT05410197: Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment |
|
|
| Recruiting | 2 | 43 | RoW | Envofolimab, Lenvatinib, Gemcitabine, Cisplatin | Sun Yat-sen University | Advanced Biliary Tract Cancer | 08/24 | 08/25 | | |
ChiCTR2200062943: Envafolimab combined with AI for the first-line treatment of advanced soft tissue sarcoma: a prospective, open-label, single arm, single-center clinical study |
|
|
| Not yet recruiting | 2 | 30 | | Envafolimab combined with AI | Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Partly self-funded, partly provied by simcere. | Soft tissue sarcoma | | | | |
NCT06055816: Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 40 | RoW | Endostar and Envafolimab | Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 09/24 | 06/28 | | |
ChiCTR2300069820: Neoadjuvant Envafolimab in Combination with Platinum-Based Chemotherapy in Resectable Stage II-IIIb Non-Small Cell Lung Cancer: a Prospective, Single-Arm Study phase II clinical study |
|
|
| Not yet recruiting | 2 | 20 | | Envafolimab plus platinum-based chemotherapy | Sichuan cancer hospital; Sichuan cancer hospital, Jiangsu Xiansheng Zaoming Pharmaceutical Co., Ltd | non-small cell lung cancer | | | | |
NCT06030934: Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albumin |
|
|
| Enrolling by invitation | 2 | 30 | RoW | envafolimab and lenvatinib combined with paclitaxel-albumin | Fudan University | Gastric / Gastroesophageal Junction Adenocarcinoma | 11/24 | 09/25 | | |
NCT05055167: Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC |
|
|
| Active, not recruiting | 2 | 20 | RoW | Envafolimab | The First Affiliated Hospital of Xiamen University | Non-small Cell Lung Cancer Stage IV | 12/24 | 06/25 | | |
RECMULRA-TNT, NCT05858567: Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Envafolimab | Sir Run Run Shaw Hospital | Rectal Cancer | 12/24 | 06/25 | | |
NCT05941325: A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 20 | RoW | fruquintinib, Envafolimab | Shanghai 6th People's Hospital | Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma | 12/25 | 12/26 | | |
NCT06108726: A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 16 | RoW | Envafolimab Injection, KN035 | Northern Jiangsu Province People's Hospital | NSCLC | 01/25 | 10/25 | | |
NCT06060704: Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC. |
|
|
| Recruiting | 2 | 33 | RoW | Envafolimab, Trifluridine/Tipiracil, TAS-102, FTD/TPI, Bevacizumab | The First Affiliated Hospital with Nanjing Medical University | Metastatic Colorectal Cancer | 03/25 | 09/25 | | |
NCT06013943: Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC |
|
|
| Recruiting | 2 | 30 | RoW | Envafolimab+Gemox | Eastern Hepatobiliary Surgery Hospital | Gallbladder Cancer | 05/25 | 12/25 | | |
ChiCTR2300069478: A single-arm, open, phase II exploratory clinical study of Envafolimab combined with Lenvatinib for neoadjuvant treatment of potentially operable liver cancer |
|
|
| Not yet recruiting | 2 | 30 | | Envafolimab combined with Lenvatinib | Shandong Provincial Hospital; Shandong Provincial Hospital, Third-party support | Liver cancer | | | | |
NCT05534113: Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC |
|
|
| Not yet recruiting | 2 | 38 | NA | Almonertinib Envafolimab | The First Affiliated Hospital with Nanjing Medical University | Non-small Cell Lung Cancer | 06/25 | 06/25 | | |
ChiCTR2300071844: Envafolimab combined with NSOX (abraxane + oxaliplatin + tegafur gimeraci) regimen for neoadjuvant therapy in gastric cancer: a one-arm, Phase II exploratory clinical trial |
|
|
| Not yet recruiting | 2 | 30 | | Enwollizumab+NSOX | First affiliated hospital of Soochow university; First affiliated hospital of Soochow university, self-finance | gastric cancer | | | | |
NCT05828381: Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer |
|
|
| Not yet recruiting | 2 | 33 | NA | Envafolimab, Abraxane, Cisplatin | Fujian Medical University Union Hospital | Immunotherapy;Envafolimab; Esophageal Cancer | 06/25 | 12/25 | | |
NCT05465733: First-line Replacement Maintenance of Envafolimab in Advanced NSCLC |
|
|
| Not yet recruiting | 2 | 25 | RoW | Envafolimab;Pemetrexed | First Affiliated Hospital Xi'an Jiaotong University | Non-Small-Cell Lung | 06/25 | 06/25 | | |
ICONIC, NCT05914389: Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer |
|
|
| Recruiting | 2 | 100 | RoW | Oxaliplatin, Capecitabine, Anti-PD-L1 Monoclonal Antibody, Envafolimab, Clostridium butyricum, Colectomy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colon Neoplasm | 08/25 | 08/30 | | |
NCT06019468: Neoadjuvant Treatment For Locally Advanced Thymic Cancer |
|
|
| Recruiting | 2 | 25 | RoW | Envolizumab combined with radiotherapy, KN035 | Shanghai Pulmonary Hospital, Shanghai, China | Thymic Carcinoma | 08/25 | 12/25 | | |
NCT06041724: Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma |
|
|
| Not yet recruiting | 2 | 46 | NA | Envafolimab combined with recombinant human endostatin and first-line chemotherapy | Fudan University | Advanced Mucosal Melanoma | 09/25 | 03/26 | | |
ChiCTR2300077763 : Phase II Study to Determine the Efficacy and Safety of RC48 in Combination with Envafolimab for Neoadjuvant Treatment in Patients with HER2 Over-expressing Muscle-Invasive Bladder Cancer |
|
|
| Not yet recruiting | 2 | 32 | | RC48 and Envafolimab | The First Affiliated Hospital, Zhejiang University School of Medicine | Bladder cancer | | | | |
NCT05910034: Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC |
|
|
| Not yet recruiting | 2 | 132 | NA | Trilaciclib+Envafolimab+Docetaxel, Envafolimab+Docetaxel, Docetaxel | Fudan University | Advanced Non-Small Cell Lung Cancer | 12/25 | 06/26 | | |
ChiCTR2300077236 :
Phase II clinical study of efficacy and safety of Envafolimab combined with albumin-paclitaxel and platinum in first-line treatment of extensive small cell lung cancer (ES-SCLC) |
|
|
| Not yet recruiting | 2 | 27 | | Envafolimab combined with albumin-paclitaxel and platinum | Zhujiang Hospital of Southern Medical University, Zhujiang Hospital of Southern Medical University | Lung cancer | | | | |
CEIL, NCT05959356: Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 198 | RoW | Cetuximab + Envafolimab + mFOLFOXIRI, Cetuximab or c225, Envafolimab, Irinotecan, Oxaliplatin, Leucovorin, 5-FU, Cetuximab + mFOLFOX6/FOLFIRI | Sun Yat-sen University | Metastatic Colorectal Cancer | 12/25 | 12/27 | | |
NCT05722977: Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients |
|
|
| Not yet recruiting | 2 | 45 | NA | Surufatinib + envafolimab | Peking Union Medical College Hospital | Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients | 02/26 | 02/27 | | |
ChiCTR2300077535 :
Clinical study on the efficacy and safety of PD-L1 antibody envafolimab combined with postoperative adjuvant chemotherapy in the treatment of pancreatic cancer |
|
|
| Recruiting | 2 | 60 | | Postoperative adjuvant chemotherapy for pancreatic cancer; chemotherapy combined with immunotherapy |
Fudan University Shanghai Cancer Center | Pancreatic cancer | | | | |
ChiCTR2200060760: Single-arm, prospective, multicenter, Phase II clinical study of Surufatinib plus Envafolimab plus Tegafur-Gimeracil-Oteracil Potassium Capsule as second-line or above therapy for advanced pancreatic cancer |
|
|
| Recruiting | 2 | 30 | | Surufatinib plus Envafolimab plus Tegafur-Gimeracil-Oteracil Potassium Capsule | Fujian Provincial Hospital; Hutchison Medipharma Co.Ltd., Hutchison Medipharma Co.Ltd., Jiangsu Simcere Pharmaceutical Co.Ltd. | advanced pancreatic cancer | | | | |
NCT05397769: Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial. |
|
|
| Recruiting | 2 | 36 | RoW | Envafolimab Plus Chemoradiotherapy | Sun Yat-sen University | Locally Advanced Nasopharyngeal Carcinoma, Envafolimab, Induction Chemotherapy, PD-L1 | 06/26 | 12/26 | | |
NCT04910386: Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers |
|
|
| Not yet recruiting | 2 | 126 | NA | Envafolimab plus Gemcitabine&Cisplatin, Gemcitabine&Cisplatin | 3D Medicines (Sichuan) Co., Ltd. | Biliary Tract Neoplasms | 06/26 | 06/27 | | |
NCT05904015: The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC |
|
|
| Not yet recruiting | 2 | 80 | NA | Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy), Hypofractionated Radiotherapy Group, Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy), Conventional Radiotherapy Group | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Lung Neoplasms | 12/26 | 06/27 | | |
NCT05799469: Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer |
|
|
| Not yet recruiting | 2 | 36 | RoW | Envafolimab, KN035, Cisplatin, External Beam Radiotherapy (EBRT), Brachytherapy (BT) | Chongqing University Cancer Hospital | Locally Advanced Cervical Cancer | 05/27 | 12/27 | | |
NCT06059261: Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. |
|
|
| Not yet recruiting | 2 | 30 | NA | Envafolimab and recombinant human endostatin combined with chemoradiotherapy | Chongqing University Cancer Hospital | Nasopharyngeal Carcinoma | 10/27 | 10/27 | | |
TRACE-LE, NCT05969847: Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer |
|
|
| Not yet recruiting | 2 | 72 | RoW | split-course hypofraction radiotherapy, hypofraction radiotherapy, CAPOX, Capecitabine+Oxaliplatin, Envafolimab, KN035, Local excision | 池畔 | Rectal Cancer | 12/27 | 12/27 | | |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 06/24 | 06/24 | | |
NCT05448820: YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma |
|
|
| Active, not recruiting | 1/2 | 15 | US | YH001, Envafolimab, KN035, Doxorubicin | Tracon Pharmaceuticals Inc. | Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma | 11/23 | 09/25 | | |
NCT05615974: A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors |
|
|
| Suspended | 1/2 | 145 | RoW | LM101, Toripalimab, Rituximab, Envafolimab | LaNova Medicines Limited | Malignant Tumors | 12/24 | 08/25 | | |
